Credit Suisse Ag Pro Qr Therapeutics N.V. Transaction History

Credit Suisse Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 12, 2020	SELL	$5.84 - $10.51 $107,397 - $193,278	-18,390 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$5.76 - $9.44 $12,902 - $21,145	2,240 Added 13.87%	18,390 $106,000
Q2 2019 Aug 14, 2019	SELL	$9.1 - $15.55 $4,877 - $8,334	-536 Reduced 3.21%	16,150 $147,000
Q1 2019 May 14, 2019	SELL	$12.5 - $18.48 $450,900 - $666,610	-36,072 Reduced 68.37%	16,686 $232,000
Q4 2018 Feb 13, 2019	SELL	$15.25 - $22.4 $318,450 - $467,756	-20,882 Reduced 28.36%	52,758 $833,000
Q3 2018 Nov 13, 2018	SELL	$6.45 - $21.6 $161,250 - $540,000	-25,000 Reduced 25.34%	73,640 $1.43 Million
Q1 2018 May 15, 2018	BUY	$2.9 - $3.5 $51,881 - $62,615	17,890 Added 22.15%	98,640 $303,000
Q4 2017 Feb 14, 2018	BUY	$2.8 - $4.8 $226,100 - $387,600	80,750	80,750 $260,000

45.1M

31.4K

24.7K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $178M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.